(2S)-4-methyl-2-[(1S)-2,2,2-trifluoro-1-(4'-methanesulfonyl-biphenyl-4-yl)ethylamino]-pentanoic acid cyanomethyl-amide | 603139-12-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-4-methyl-2-[(1S)-2,2,2-trifluoro-1-(4'-methanesulfonyl-biphenyl-4-yl)ethylamino]-pentanoic acid cyanomethyl-amide
• 英文别名: L-873724；N¹-(cyanomethyl)-N²-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide；N¹-(cyanomethyl)-N²{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide；N1-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide；N1-(cyanomethyl)-N2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide；Pentanamide, N-(cyanomethyl)-4-methyl-2-(((1S)-2,2,2-trifluoro-1-(4'-(methylsulfonyl)(1,1'-biphenyl)-4-yl)ethyl)amino)-, (2S)-；(2S)-N-(cyanomethyl)-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4-(4-methylsulfonylphenyl)phenyl]ethyl]amino]pentanamide
• CAS: 603139-12-4
• 化学式: C₂₃H₂₆F₃N₃O₃S
• 分子量: 481.539
• InChiKey: VYFDSJLOCIGIKP-SFTDATJTSA-N

物化性质

• 溶解度：
  溶于二甲基亚砜

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  33
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  107
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  (2S)-4-methyl-2-[(1S)-2,2,2-trifluoro-1-(4'-methanesulfonyl-biphenyl-4-yl)ethylamino]-pentanoic acid cyanomethyl-amide 在 tritium oxide 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 四氢呋喃 为溶剂， 生成 (2S)-N-(cyanomethyl)-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4-[4-(tritritiomethylsulfonyl)phenyl]phenyl]ethyl]amino]pentanamide
  参考文献：
  名称：

  A generally applicable method for assessing the electrophilicity and reactivity of diverse nitrile-containing compounds

  摘要：

  Nitrile-based inhibitors of cathepsin K have been known for some time and mechanism-of-action studies have demonstrated that cysteinyl proteases interact with nitriles in a reversible fashion. Three main classes of nitrile-containing inhibitors have been published in the cathepsin K field: (i) cyanamides, (ii) aromatic nitriles, and (iii) aminoacetonitriles. A computational approach was used to calculate the theoretical reactivities of diverse nitriles and this was found to correlate with their extent of reactivity with free cysteine. Moreover, there is a tentative link between high reactivity with cysteine and the potential to lead to irreversible covalent binding to proteins. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.11.044
• 作为产物：
  描述：

  L-亮氨醇 在 palladium diacetate chromium(VI) oxide 、 4-二甲氨基吡啶 、 sodium tungstate 、 正丁基锂 、 双氧水 、 四丁基硫酸氢铵 、 4-(dimethylamino)pyridine hydrochloride 、 sodium carbonate 、 高碘酸 、 三乙胺 、 三苯基膦 、 三氟乙酸 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 四氢呋喃 、 丙醇 、 正己烷 、 水 、 N,N-二甲基甲酰胺 、 甲苯 、 乙腈 为溶剂， 反应 30.75h， 生成 (2S)-4-methyl-2-[(1S)-2,2,2-trifluoro-1-(4'-methanesulfonyl-biphenyl-4-yl)ethylamino]-pentanoic acid cyanomethyl-amide
  参考文献：
  名称：

  Diastereoselective Arylithium Addition to an α-Trifluoromethyl Imine. Practical Synthesis of a Potent Cathepsin K Inhibitor

  摘要：

  A practical, chromatography-free synthesis of potent cathepsin K inhibitor 1 is described. The addition of 4-bromophenyllithium to an alpha-trifluoromethylimine derived from commercially available (S)-leucinol was accomplished in a highly diastereoselective manner (97.6% de, 91% yield). Subsequent Suzuki cross-coupling afforded biaryl 7. Oxidation of the alcohol and sulfide functionalities led to the formation of carboxylic acid 8. Crystallization of 7 and acid 8 as its dicyclohexylamine salt gave excellent impurity rejection. The final amide coupling with commercially available aminoacetonitrile hydrochloride afforded 1 in excellent purity (99.6A% by HPLC, 100% de, < 3 ppm Pd, W, Cr).

  DOI：

  10.1021/jo052430j

文献信息

• Primary amides as selective inhibitors of cathepsin K
  作者：Serge Léger、Christopher I. Bayly、W. Cameron Black、Sylvie Desmarais、Jean-Pierre Falgueyret、Frédéric Massé、M. David Percival、Jean-François Truchon

  DOI：10.1016/j.bmcl.2007.05.024

  日期：2007.8

  The nitrile warhead used in a series of cathepsin K inhibitors can be replaced by a less electrophilic primary amide. The accompanying loss of potency can be partially recovered by introducing a substituent alpha to the amide. The potency gain resulting from this addition is not achieved with the nitrile derivatives due to a different geometry of the cysteine adduct in the enzyme active site. This

  一系列组织蛋白酶K抑制剂中使用的腈弹头可以用亲电性较低的伯酰胺代替。通过将取代基α引入酰胺中，可以部分地弥补伴随的效力损失。由于腈活性衍生物在酶活性位点中半胱氨酸加合物的几何形状不同，因此用腈衍生物不能实现这种添加所带来的效价提高。这项研究导致鉴定了作为抑制底物的伯酰胺2g，对组织蛋白酶K的IC（50）为10 nM，与其他组织蛋白酶相比具有出色的选择性。
• [EN] CATHEPSIN CYSTEINE PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE CATHEPSINE ET DE CYSTEINE PROTEASE
  申请人：MERCK FROSST CANADA INC

  公开号：WO2005019161A1

  公开（公告）日：2005-03-03

  This invention relates to a novel class of compounds, represented by the formula below, wherein the meanings of G, E, E, n, R1, R2, R3 et R4 are indicated therein, which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

  本发明涉及一类新颖的化合物，其由下述公式表示，其中G、E、E、n、R1、R2、R3和R4的含义如公式中所示，这些化合物是半胱氨酸蛋白酶抑制剂，包括但不限于组织蛋白酶K、L、S和B的抑制剂。这些化合物可用于治疗那些指示抑制骨吸收的疾病，例如骨质疏松症。
• [EN] CATHEPSIN INHIBITORS<br/>[FR] INHIBITEURS DE LA CATHEPSINE
  申请人：MERCK FROSST CANADA INC

  公开号：WO2005021487A1

  公开（公告）日：2005-03-10

  This invention relates to a novel class of compounds, represented by the formula (I) below, wherein the meanings of R1, R2, R3 and R4 are indicated therein, which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis, osteoarthritis and rheumatoid arthritis.

  这项发明涉及一类新型化合物，由下式（I）表示，其中R1、R2、R3和R4的含义已在其中指示，这些化合物是半胱氨酸蛋白酶抑制剂，包括但不限于对卡特普辛K、L、S和B的抑制剂。这些化合物对于治疗需要抑制骨吸收的疾病非常有用，如骨质疏松症、骨关节炎和类风湿性关节炎。
• Cathepsin cysteine protease inhibitors
  申请人：——

  公开号：US20030232863A1

  公开（公告）日：2003-12-18

  This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

  这项发明涉及一类新型化合物，它们是半胱氨酸蛋白酶抑制剂，包括但不限于对卡特普辛K、L、S和B的抑制剂。这些化合物可用于治疗需要抑制骨吸收的疾病，如骨质疏松症。
• Identification of a potent and selective non-basic cathepsin K inhibitor
  作者：Chun Sing Li、Denis Deschenes、Sylvie Desmarais、Jean-Pierre Falgueyret、Jacques Yves Gauthier、Donald. B. Kimmel、Serge Léger、Frédéric Massé、Mary E. McGrath、Daniel J. McKay、M. David Percival、Denis Riendeau、Sevgi B. Rodan、Michel Thérien、Vouy-Linh Truong、Gregg Wesolowski、Robert Zamboni、W. Cameron Black

  DOI：10.1016/j.bmcl.2005.12.071

  日期：2006.4

  Based on our previous study with trifluoroethylamine as a P2-P3 amide isostere of cathepsin K inhibitor, further optimization led to identification of compound 22 (L-873724) as a potent and selective non-basic cathepsin K inhibitor. This compound showed excellent pharmacokinetics and efficacy in an ovariectomized (OVX) rhesus monkey model. The volumes of distribution close to unity were consistent

  基于我们先前使用三氟乙胺作为组织蛋白酶K抑制剂的P2-P3酰胺等位异构体的研究，进一步的优化导致化合物22（L-873724）被鉴定为有效的和选择性的非碱性组织蛋白酶K抑制剂。该化合物在卵巢切除（OVX）恒河猴模型中显示出出色的药代动力学和功效。接近统一的分布体积与该化合物不是溶血同质性一致，这是碱性组织蛋白酶K抑制剂的特征。